Drug Profile
Research programme: bacteriophage therapeutics - Armata Pharmaceuticals
Alternative Names: ESKAPE Pathogens bacteriophagesLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Biocontrol
- Developer Armata Pharmaceuticals
- Class Antibacterials; Bacteriophages
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acinetobacter infections; Enterococcal infections; Klebsiella infections; Staphylococcal infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Acinetobacter-infections in USA
- 28 Feb 2022 No recent reports of development identified for preclinical development in Enterococcal-infections in USA
- 28 Feb 2022 No recent reports of development identified for preclinical development in Klebsiella-infections in USA